ACCORD-UK LTD

Manufacture of pharmaceutical preparations

Information

Name

ACCORD-UK LTD

Type

Manufacture of pharmaceutical preparations

Roles

Supplier

Company Size

Large

Company Number

00079585

Incorporation Date

1903-12-30 00:00:00

Website

https://www.accord-healthcare.com/

Address

Barnstaple

United Kingdom

Suppliers

Unlock the full supplier list, free!

Sign up to unlock the full list of suppliers associated with ACCORD-UK LTD
Sign up free

Contracts awarded to ACCORD-UK LTD

The contracts that ACCORD-UK LTD have been awarded to supply. Click on the contract to view more detailed information and view the full details about the contract won.

Award

Published 3 weeks ago

NP39724b Pomalidomide and Thalidomide

Supply of pomalidomide capsules and thalidomide capsules to NHS Scotland.

£959,680
Award

Published 4 weeks ago

Generic, Branded Generic & Proprietary Medicinal Products - Group 15

Generic, Branded Generic & Proprietary Medicinal Products - Group 15 (5417226)

£10,593,948
Award

Published 2 months ago

NHS National Generic Pharmaceuticals Wave 15a

NHS National Generic Pharmaceuticals - Wave 15a. Offer reference number: CM/PHG/23/5697. Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 48 months. Potential periods of call-offs under the framework agreement: CM/PHG/23/5697/01 – Orals (plus non-parenteral) Products: All Regions (CESW/LSNE/NWLN): 01/02/2025 to 31/05/2027 (28 Months) CM/PHG/23/5697/02 – Hospital Only Products: DNW & DLN: 01/02/2025 to 31/01/2027 (24 months) CM/PHG/23/5697/03 – Hospital Only Products (Housekeeping): DLS & DNE: 01/02/2025 to 31/05/2026 (16 months) DCE & DSW: 01/02/2025 to 30/09/2025 (8 months)

£170
Award

Published 4 months ago

NHS National Framework for Transition products commencing 1 October 2024

Project title: NHS National Framework for Transition products commencing 1 October 2024 Offer reference number: CM/TNS/24/5712 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum of 24 months. Potential periods of call-offs under the framework agreement: CM/TNS/24/5712/01 - Amphotericin liposomal Injection, bexarotene capsules, dabigatran capsules, plerixafor injection and rivaroxaban tablets Lot 1 CESW: 01/10/2024 to 30/09/2025 (12 months) Lot 2 NWLN: 01/10/2024 to 30/09/2025 (12 months) Lot 3 LSNE: 01/10/2024 to 31/05/2026 (20 months) CM/TNS/24/5712/02 - Imatinib Lot 1 DSW: 01/10/2024 to 30/09/2025 (12 months) Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England

£41,320,000 Bids close: 6 months ago
Award

Published 4 months ago

NHS National Framework for Transition products commencing 1 October 2024

Project title: NHS National Framework for Transition products commencing 1 October 2024 Offer reference number: CM/TNS/24/5712 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum of 24 months. Potential periods of call-offs under the framework agreement: CM/TNS/24/5712/01 - Amphotericin liposomal Injection, bexarotene capsules, dabigatran capsules, plerixafor injection and rivaroxaban tablets Lot 1 CESW: 01/10/2024 to 30/09/2025 (12 months) Lot 2 NWLN: 01/10/2024 to 30/09/2025 (12 months) Lot 3 LSNE: 01/10/2024 to 31/05/2026 (20 months) CM/TNS/24/5712/02 - Imatinib Lot 1 DSW: 01/10/2024 to 30/09/2025 (12 months) Published By: Medicines Procurement and Supply Chain – NHS Medicines Value & Access, NHS England

£13
Award

Published 5 months ago

CM/TNS/24/5711 -NHS Framework for the supply of Ustekinumab

Project title: NHS National Framework for the supply of Ustekinumab 1 September 2024 Offer reference number: CM/TNS/24/5711 CM/TNS/24/5711/01 - NHS Framework for the supply of Ustekinumab - London & South of England. Period of framework: 1 September 2024 to 31 August 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/TNS/24/5711/02 - NHS Framework for the supply of Ustekinumab - North of England and Midlands & East. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England

£230,000,000 Bids close: 7 months ago

Contacts

+44 7919830195

[email protected]

+44 7919830195

Statistics (1 Year)

Contracts Won

Total Won

£67,499,291

Average Win

£16,874,823

ACCORD-UK LTD

Information

Name

Type

Roles

Company Size

Company Number

Incorporation Date

Website

Address

Suppliers

Contracts awarded to ACCORD-UK LTD

NP39724b Pomalidomide and Thalidomide

Generic, Branded Generic & Proprietary Medicinal Products - Group 15

NHS National Generic Pharmaceuticals Wave 15a

NHS National Framework for Transition products commencing 1 October 2024

NHS National Framework for Transition products commencing 1 October 2024

CM/TNS/24/5711 -NHS Framework for the supply of Ustekinumab

Contacts

Statistics (1 Year)

Contracts Won

Total Won

Average Win